Changes within the growth hormone/insulin-like growth factor I/IGF binding protein axis during critical illness.

[1]  J. Merchant,et al.  Inhibition of growth hormone receptor gene expression by saturated fatty acids: role of Kruppel-like zinc finger factor, ZBP-89. , 2006, Molecular endocrinology.

[2]  Adrian V. Lee,et al.  Liver-specific overexpression of the insulin-like growth factor-I enhances somatic growth and partially prevents the effects of growth hormone deficiency. , 2006, Endocrinology.

[3]  D. Chinkes,et al.  Beneficial Effects of Extended Growth Hormone Treatment After Hospital Discharge in Pediatric Burn Patients , 2006, Annals of surgery.

[4]  P. Kelly,et al.  Growth hormone promotes skeletal muscle cell fusion independent of insulin-like growth factor 1 up-regulation. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Lindholm,et al.  Growth hormone: Historical notes , 2006, Pituitary.

[6]  P. Déchelotte,et al.  L-alanyl-L-glutamine dipeptide–supplemented total parenteral nutrition reduces infectious complications and glucose intolerance in critically ill patients: The French controlled, randomized, double-blind, multicenter study* , 2006, Critical care medicine.

[7]  C. Hinds,et al.  Treatment with GH and IGF-1 in critical illness. , 2006, Critical care clinics.

[8]  J. Ketelslegers,et al.  Insulin-like growth factor-I gene transfer by electroporation prevents skeletal muscle atrophy in glucocorticoid-treated rats. , 2005, Endocrinology.

[9]  Choh Hao Li,et al.  Human pituitary growth hormone , 1964, Experientia.

[10]  G. Van den Berghe,et al.  Regulation of the somatotropic axis by intensive insulin therapy during protracted critical illness. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  G. Van den Berghe,et al.  Endocrine and metabolic effects of growth hormone (GH) compared with GH-releasing peptide, thyrotropin-releasing hormone, and insulin infusion in a rabbit model of prolonged critical illness. , 2004, Endocrinology.

[12]  P. Carroll,et al.  Combined growth hormone/insulin-like growth factor I in addition to glutamine-supplemented TPN results in net protein anabolism in critical illness. , 2004, American journal of physiology. Endocrinology and metabolism.

[13]  K. Nakao,et al.  Alterations of plasma ghrelin levels in rats with lipopolysaccharide-induced wasting syndrome and effects of ghrelin treatment on the syndrome. , 2003, Endocrinology.

[14]  G. Van den Berghe,et al.  Growth hormone modulation of the rat hepatic bile transporter system in endotoxin-induced cholestasis. , 2003, Endocrinology.

[15]  G. Brabant.  Insulin-like growth factor-I: marker for diagnosis of acromegaly and monitoring the efficacy of treatment. , 2003, European journal of endocrinology.

[16]  P. Sönksen,et al.  The role of the growth hormone–insulin‐like growth factor axis in glucose homeostasis , 2003, Diabetic medicine : a journal of the British Diabetic Association.

[17]  C. Hinds,et al.  Anabolic strategies in critical illness. , 2002, Current opinion in pharmacology.

[18]  G. Van den Berghe,et al.  Regulation of insulin-like growth factor binding protein-1 during protracted critical illness. , 2002, The Journal of clinical endocrinology and metabolism.

[19]  G. Berghe.  Dynamic neuroendocrine responses to critical illness , 2002, Frontiers in Neuroendocrinology.

[20]  R. Baxter,et al.  Regulation of the acid-labile subunit in sustained endotoxemia. , 2002, American journal of physiology. Endocrinology and metabolism.

[21]  G. Van den Berghe,et al.  The combined administration of GH‐releasing peptide‐2 (GHRP‐2), TRH and GnRH to men with prolonged critical illness evokes superior endocrine and metabolic effects compared to treatment with GHRP‐2 alone , 2002, Clinical endocrinology.

[22]  C. Lang,et al.  Role of growth hormone, insulin-like growth factor-I, and insulin-like growth factor binding proteins in the catabolic response to injury and infection , 2002, Current opinion in clinical nutrition and metabolic care.

[23]  E. Ruokonen,et al.  Dangers of growth hormone therapy in critically ill patients , 2002, Current opinion in clinical nutrition and metabolic care.

[24]  G. Van den Berghe,et al.  A novel in vivo rabbit model of hypercatabolic critical illness reveals a biphasic neuroendocrine stress response. , 2002, Endocrinology.

[25]  M Schetz,et al.  Intensive insulin therapy in critically ill patients. , 2001, The New England journal of medicine.

[26]  C. Pichard,et al.  Management of catabolism in metabolically stressed patients: a literature survey about growth hormone application , 2001, Current opinion in clinical nutrition and metabolic care.

[27]  G. Ooi,et al.  The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system. , 2001, The Journal of endocrinology.

[28]  G. Van den Berghe,et al.  Safety aspects of pharmacological GH therapy in adults. , 2001, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[29]  J. Frystyk,et al.  Liver-specific igf-1 gene deletion leads to muscle insulin insensitivity. , 2001, Diabetes.

[30]  A. Revhaug,et al.  High-dose growth hormone does not affect proinflammatory cytokine (tumor necrosis factor-alpha, interleukin-6, and interferon-gamma) release from activated peripheral blood mononuclear cells or after minimal to moderate surgical stress. , 2000, The Journal of clinical endocrinology and metabolism.

[31]  G. V. Berghe,et al.  Novel insights into the neuroendocrinology of critical illness , 2000 .

[32]  D. Clemmons,et al.  Assessment of growth parameters and life span of GHR/BP gene-disrupted mice. , 2000, Endocrinology.

[33]  R. Wolfe,et al.  Changes in Intermediary Metabolism in Severe Surgical Illness , 2000, World Journal of Surgery.

[34]  R. Baxter.  Insulin-like growth factor (IGF)-binding proteins: interactions with IGFs and intrinsic bioactivities. , 2000, American journal of physiology. Endocrinology and metabolism.

[35]  G. Van den Berghe,et al.  A paradoxical gender dissociation within the growth hormone/insulin-like growth factor I axis during protracted critical illness. , 2000, The Journal of clinical endocrinology and metabolism.

[36]  M. Nakazato,et al.  Ghrelin is a growth-hormone-releasing acylated peptide from stomach , 1999, Nature.

[37]  P. Carroll.  Protein metabolism and the use of growth hormone and insulin-like growth factor-I in the critically ill patient. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[38]  D. Chinkes,et al.  Anabolic effects of insulin-like growth factor in combination with insulin-like growth factor binding protein-3 in severely burned adults. , 1999, The Journal of trauma.

[39]  P. Cohen,et al.  Novel aspects of the insulin-like growth factor binding proteins. , 1999, Molecular genetics and metabolism.

[40]  N R Webster,et al.  Increased mortality associated with growth hormone treatment in critically ill adults. , 1999, The New England journal of medicine.

[41]  D. Leroith,et al.  Normal growth and development in the absence of hepatic insulin-like growth factor I. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[42]  R. Baxter.  The insulin-like growth factor (IGF)-IGF-binding protein axis in critical illness. , 1999, Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society.

[43]  G. Van den Berghe,et al.  Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness. , 1999, The Journal of clinical endocrinology and metabolism.

[44]  J. Ketelslegers,et al.  GH insensitivity induced by endotoxin injection is associated with decreased liver GH receptors. , 1999, American journal of physiology. Endocrinology and metabolism.

[45]  J. A. Scarlett,et al.  Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy, and urinary albumin excretion in experimental diabetes in mice. , 1999, Diabetes.

[46]  Wilmore Dw.  The use of growth hormone in severely ill patients. , 1999 .

[47]  R. Baxter,et al.  Thrity-day monitoring of insulin-like growth factors and their binding proteins in intensive care unit patients , 1998 .

[48]  J. Veldhuis,et al.  Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. , 1998, Endocrine reviews.

[49]  G. Van den Berghe,et al.  Leptin levels in protracted critical illness: effects of growth hormone-secretagogues and thyrotropin-releasing hormone. , 1998, The Journal of clinical endocrinology and metabolism.

[50]  G. Van den Berghe,et al.  Clinical review 95: Acute and prolonged critical illness as different neuroendocrine paradigms. , 1998, The Journal of clinical endocrinology and metabolism.

[51]  Stephen Twigg,et al.  Insulin-like Growth Factor (IGF)-binding Protein 5 Forms an Alternative Ternary Complex with IGFs and the Acid-labile Subunit* , 1998, The Journal of Biological Chemistry.

[52]  G. Van den Berghe,et al.  Neuroendocrinology of prolonged critical illness: effects of exogenous thyrotropin-releasing hormone and its combination with growth hormone secretagogues. , 1998, The Journal of clinical endocrinology and metabolism.

[53]  R. Baxter.  The binding protein's binding protein--clinical applications of acid-labile subunit (ALS) measurement. , 1997, The Journal of clinical endocrinology and metabolism.

[54]  D. Prough,et al.  Acute alterations in growth hormone-insulin-like growth factor axis in humans injected with endotoxin. , 1997, The American journal of physiology.

[55]  M. Rechler,et al.  Growth hormone stimulates transcription of the gene encoding the acid-labile subunit (ALS) of the circulating insulin-like growth factor-binding protein complex and ALS promoter activity in rat liver. , 1997, Molecular endocrinology.

[56]  J. Wernerman,et al.  Measurement of human growth hormone receptor messenger ribonucleic acid by a quantitative polymerase chain reaction-based assay: demonstration of reduced expression after elective surgery. , 1997, The Journal of clinical endocrinology and metabolism.

[57]  G. Van den Berghe,et al.  The somatotropic axis in critical illness: effect of continuous growth hormone (GH)-releasing hormone and GH-releasing peptide-2 infusion. , 1997, The Journal of clinical endocrinology and metabolism.

[58]  G. Van den Berghe,et al.  Pituitary responsiveness to GH‐releasing hormone, GH‐releasing peptide‐2 and thyrotrophin‐releasing hormone in critical illness , 1996, Clinical endocrinology.

[59]  J. Holly,et al.  Critical illness is associated with low circulating concentrations of insulin-like growth factors-I and -II, alterations in insulin-like growth factor binding proteins, and induction of an insulin-like growth factor binding protein 3 protease. , 1996, Critical care medicine.

[60]  Patrick R. Griffin,et al.  A Receptor in Pituitary and Hypothalamus That Functions in Growth Hormone Release , 1996, Science.

[61]  U. Keller,et al.  Metabolic actions of growth hormone: direct and indirect. , 1996, Bailliere's clinical endocrinology and metabolism.

[62]  P. Essén,et al.  A descriptive study of skeletal muscle metabolism in critically ill patients: free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes. , 1996, Critical care medicine.

[63]  B. Angelin,et al.  Growth hormone potentiates the in vivo biological activities of endotoxin in the rat , 1996, European journal of clinical investigation.

[64]  W. Blum,et al.  The differential regulation of the circulating levels of the insulin‐like growth factors and their binding proteins (IGFBP) 1, 2 and 3 after elective abdominal surgery , 1996, Clinical endocrinology.

[65]  R. Baxter.  Insulin-like growth factor binding proteins as glucoregulators. , 1995, Metabolism: clinical and experimental.

[66]  G. Striker,et al.  Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. , 1995, Endocrinology.

[67]  G. Van den Berghe,et al.  Growth hormone secretion in critical illness: effect of dopamine. , 1994, The Journal of clinical endocrinology and metabolism.

[68]  K. Brismar,et al.  Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. , 1994, The Journal of clinical endocrinology and metabolism.

[69]  M. Binoux,et al.  Insulin-like growth factor binding protein-3 is functionally altered in pregnancy plasma. , 1994, Endocrinology.

[70]  D. Löhlein,et al.  Repeated administration of recombinant human insulin-like growth factor-I in patients after gastric surgery. Effect on metabolic and hormonal patterns. , 1993 .

[71]  K. Alberti,et al.  A low dose euglycemic infusion of recombinant human insulin-like growth factor I rapidly suppresses fasting-enhanced pulsatile growth hormone secretion in humans. , 1993, The Journal of clinical investigation.

[72]  R. Baxter,et al.  Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. , 1993, The Journal of clinical investigation.

[73]  R. S. V. STRACK VAN SCHIJNDEL,et al.  Effects of Recombinant Human Growth Hormone in Patients With Severe Sepsis , 1992, Annals of surgery.

[74]  D. Clemmons,et al.  Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. , 1992, The Journal of clinical endocrinology and metabolism.

[75]  K. Alberti,et al.  Augmented growth hormone (GH) secretory burst frequency and amplitude mediate enhanced GH secretion during a two-day fast in normal men. , 1992, The Journal of clinical endocrinology and metabolism.

[76]  J. Holly,et al.  The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. , 1991, The Journal of endocrinology.

[77]  J. Miell,et al.  Critically ill patients have high basal growth hormone levels with attenuated oscillatory activity associated with low levels of insulin–like growth factor‐I , 1991, Clinical endocrinology.

[78]  R. Wolfe,et al.  Effect of exogenous growth hormone on whole-body and isolated-limb protein kinetics in burned patients. , 1991, Archives of surgery.

[79]  M. Lamy,et al.  Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. , 1989, Critical care medicine.

[80]  A. Beddoe,et al.  Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients. , 1987, The Journal of trauma.

[81]  F. Momany,et al.  On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. , 1984, Endocrinology.

[82]  W. Vale,et al.  Characterization of a growth hormone-releasing factor from a human pancreatic islet tumour , 1982, Nature.

[83]  N. Ling,et al.  Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. , 1982, Science.

[84]  F. Cerra,et al.  Septic Autocannibalism: A Failure of Exogenous Nutritional Support , 1980, Annals of surgery.

[85]  N. Ling,et al.  Hypothalamic Polypeptide That Inhibits the Secretion of Immunoreactive Pituitary Growth Hormone , 1973, Science.

[86]  W. Liu,et al.  Human pituitary growth hormone. XIX. The primary structure of the hormone. , 1969, Archives of biochemistry and biophysics.

[87]  W. Daughaday,et al.  A hormonally controlled serum factor which stimulates sulfate incorporation by cartilage in vitro. , 1957, The Journal of laboratory and clinical medicine.

[88]  C. Li,et al.  THE ISOLATION OF PITUITARY GROWTH HORMONE. , 1944, Science.